Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.54 |
| ▸ | FSHR | P23945 | 7/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 2/20 | 0.35 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.35 |
| ▸ | GLRB | P48167 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2192651 | 0.86 | FSHR (0.55) | TSHRFSHRNPC1SMN1; SMN2KMT2A | |
| SCHEMBL2192843 | 0.84 | TSHR (0.65) | TSHRFSHRNPC1SMN1; SMN2 | |
| SCHEMBL2191283 | 0.81 | FSHR (0.56) | TSHRFSHRNPC1SMN1; SMN2LMNA | |
| SCHEMBL2192816 | 0.81 | FSHR (0.56) | TSHRFSHRNPC1SMN1; SMN2KMT2A | |
| SCHEMBL2192026 | 0.73 | TSHR (0.68) | TSHRFSHR | |
| SCHEMBL2192500 | 0.73 | TSHR (0.50) | TSHRFSHRNPC1SMN1; SMN2LMNA | |
| SCHEMBL2192676 | 0.72 | TSHR (0.64) | TSHRFSHR | |
| SCHEMBL2194165 | 0.71 | TSHR (0.65) | TSHRFSHR | |
| SCHEMBL2193680 | 0.70 | TSHR (1.00) | TSHRFSHR | |
| SCHEMBL2192533 | 0.70 | FSHR (0.66) | TSHRFSHRNPC1SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172267-A1 | TSH receptor antagonizing tetrahydroquinoline compounds | N.V. ORGANON | 2011-07-14 | — | — | US | claimed |
| EP-2197445-A2 | TSH RECEPTOR ANTAGONIZING TETRAHYDROQUINOLINE COMPOUNDS | N.V. Organon (NL) | 2010-06-23 | — | — | EP | claimed |
| WO-2009027482-A2 | TSH RECEPTOR ANTAGONIZING TETRAHYDROQUINOLINE COMPOUNDS | N.V. ORGANON (NL) | 2009-03-05 | — | — | WO | claimed |
| EP-2197445-B1 | TSH RECEPTOR ANTAGONIZING TETRAHYDROQUINOLINE COMPOUNDS | MERCK SHARP & DOHME (NL) | 2017-04-19 | — | — | EP | disclosed |
| US-9174940-B2 | TSH receptor antagonizing tetrahydroquinoline compounds | MERCK SHARP & DOHME B.V. (NL) | 2015-11-03 | — | — | US | disclosed |
| US-20110172267-A1 | TSH receptor antagonizing tetrahydroquinoline compounds | N.V. ORGANON | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172267-A1 | TSH receptor antagonizing tetrahydroquinoline compounds | TSHR, MC1R, TRHR | TSHR 1/4885FSHR 21/4885NPC1 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.